Suppr超能文献

手术、克罗恩病与生物时代:是否产生影响?

Surgery, Crohn's disease, and the biological era: has there been an impact?

机构信息

Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland.

出版信息

J Clin Gastroenterol. 2011 Sep;45(8):691-3. doi: 10.1097/MCG.0b013e318201ff96.

Abstract

INTRODUCTION

The management of Crohn's disease (CD) has changed considerably over the last 20 years. Immunomodulators and biological therapies now play a role in treating patients with CD, but little is known of their influence on surgical rates.

AIM

To review the surgery rates for CD in an Irish university hospital over a 20-year period and to determine whether newer therapies had an impact on surgical rates.

METHOD

Seven hundred twenty-two patients attending St Vincent's University Hospital, Dublin, with CD over a 20-year period (January 1986 to December 2005) were identified. The patients were divided into quartiles. Resection rates were determined in all the quartiles, at both 1 and 3 years from diagnosis.

RESULTS

A decline in surgery, 3 years from diagnosis, was noted between the first quartile (72 patients, 40%) and the second quartile (58 patients, 32%; P=0.03). No significant change in surgical rates at 3 years occurred between the other 3 quartiles (32%, 30%, and 35%, respectively; P=NS). The patients who required a resection within 3 years were diagnosed at a younger age in later years. There was a similar predominance of 60% of female patients requiring surgery in all groups. The patients requiring surgery were twice as likely to be ex-smokers or current smokers in all groups. Use of infliximab, within 3 years from diagnosis, increased from 0, 0, and 16 patients (8.8%) to 40 patients (22.1%) in the last quartile. The majority of patients were treated with infliximab on an "on demand" basis. Use of infliximab earlier within the course of the disease was seen in later quartiles (ie, within 1 y of diagnosis): 0, 0, 6, and 21 patients.

CONCLUSION

Despite the introduction of infliximab over the past 10 years, no demonstrable difference has been seen in the rates of patients requiring resection surgery within 3 years of diagnosis. The reasons for this are unclear, but may relate to episodic treatment, rather than regular maintenance treatment. Female patients and smokers seem to be particularly at risk of resection surgery.

摘要

简介

在过去的 20 年中,克罗恩病(CD)的治疗方法发生了很大的变化。免疫调节剂和生物疗法现在在治疗 CD 患者中发挥了作用,但对手术率的影响知之甚少。

目的

回顾爱尔兰一家大学医院 20 年来 CD 的手术率,并确定新疗法是否对手术率有影响。

方法

确定了 1986 年 1 月至 2005 年 12 月期间在都柏林圣文森特大学医院就诊的 722 例 CD 患者。患者分为四组。确定了所有四组的切除率,从诊断后 1 年和 3 年。

结果

与第一组(72 例,40%)和第二组(58 例,32%;P=0.03)相比,从诊断后 3 年开始,手术率下降。在其他三组(分别为 32%、30%和 35%)之间,3 年后手术率无明显变化(P=NS)。在以后的年份中,需要在 3 年内进行切除的患者的诊断年龄较小。在所有组中,需要手术的患者中有 60%是女性。在所有组中,需要手术的患者中,既往吸烟者或当前吸烟者的比例均为两倍。在诊断后 3 年内,英夫利昔单抗的使用率从 0、0 和 16 例(8.8%)增加到最后一组的 40 例(22.1%)。大多数患者都是按需接受英夫利昔单抗治疗。在疾病的早期阶段(即诊断后 1 年内)更早使用英夫利昔单抗,见 0、0、6 和 21 例患者。

结论

尽管在过去 10 年中引入了英夫利昔单抗,但在诊断后 3 年内需要进行切除手术的患者比例没有明显差异。原因尚不清楚,但可能与间歇性治疗而不是常规维持治疗有关。女性患者和吸烟者似乎特别有接受切除术的风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验